Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $9.00.

PYXS has been the subject of a number of recent analyst reports. Stephens assumed coverage on Pyxis Oncology in a report on Friday, November 8th. They issued an "overweight" rating and a $13.00 price objective for the company. Royal Bank of Canada reissued an "outperform" rating and issued a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. HC Wainwright reissued a "buy" rating and set a $5.00 price target (down from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, William Blair downgraded shares of Pyxis Oncology from an "outperform" rating to a "market perform" rating in a report on Thursday, November 21st.

Insider Transactions at Pyxis Oncology

In other news, CFO Pamela Ann Connealy bought 88,850 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was bought at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the acquisition, the chief financial officer now directly owns 1,199,143 shares in the company, valued at $2,350,320.28. This represents a 8.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 9.80% of the company's stock.

Institutional Trading of Pyxis Oncology

Hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. acquired a new position in shares of Pyxis Oncology in the third quarter worth $1,405,000. Geode Capital Management LLC grew its stake in Pyxis Oncology by 5.5% in the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company's stock valued at $3,982,000 after purchasing an additional 57,016 shares in the last quarter. abrdn plc increased its position in Pyxis Oncology by 28.9% in the 3rd quarter. abrdn plc now owns 913,045 shares of the company's stock worth $3,351,000 after purchasing an additional 204,742 shares during the last quarter. Millennium Management LLC raised its stake in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock worth $4,425,000 after purchasing an additional 743,499 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Pyxis Oncology by 275.0% in the 3rd quarter. Barclays PLC now owns 64,089 shares of the company's stock valued at $235,000 after buying an additional 46,997 shares in the last quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Stock Up 0.7 %

NASDAQ PYXS traded up $0.01 on Friday, hitting $1.51. The stock had a trading volume of 361,855 shares, compared to its average volume of 562,107. The company's 50-day moving average is $1.64 and its two-hundred day moving average is $2.91. Pyxis Oncology has a one year low of $1.39 and a one year high of $6.85. The stock has a market cap of $89.80 million, a price-to-earnings ratio of -1.47 and a beta of 1.06.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.